CLEC1B and venous thromboembolism: Podoplanin is involved in lymphatic development [61] and platelet activation since CLEC2 is the only known podoplanin receptor ligand in the context of inflammatory haemostasis [62] and represents an additional risk of venous thromboembolism in COVID-19 patients because many of the systemically released cytokines present a prothrombotic effect in patients [63].